<DOC>
	<DOCNO>NCT00352001</DOCNO>
	<brief_summary>RATIONALE : Lenalidomide may stop growth cancer cell block blood flow cancer . Lenalidomide may also stimulate immune system different way stop cancer cell grow . Drugs use chemotherapy , azacitidine , work different way stop growth cancer cell , either kill cell stop dividing . Azacitidine may also cause cancer cell look like normal cell , grow spread slowly . Giving lenalidomide together azacitidine may kill cancer cell . PURPOSE : This phase I trial study side effect best dose lenalidomide azacitidine treat patient advanced myelodysplastic syndrome .</brief_summary>
	<brief_title>Lenalidomide Azacitidine Treating Patients With Advanced Myelodysplastic Syndromes</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose dose-limiting toxicity lenalidomide azacitidine patient advance myelodysplastic syndrome ( MDS ) . Secondary - Review clinical outcome , define International Working Group criterion , patient treat regimen . - Determine time transformation acute myeloid leukemia death patient treat regimen . - Determine time relapse achieve complete partial remission patient treat regimen . - Determine time disease progression patient treat regimen . - Determine effect regimen hematologic status ( include peripheral blood count need platelet and/or red blood cell transfusion ) patient . OUTLINE : This open-label , multicenter , dose-escalation study . Patients receive oral lenalidomide daily day 1-14 day 1-21 azacitidine subcutaneously daily day 1-5 day 1-5 8-12 . Treatment repeat every 28 day 7 course absence relapse ( achieve complete partial remission ) , disease progression , unacceptable toxicity . Cohorts 3-6 patient receive escalate dos and/or increase dose frequency lenalidomide azacitidine maximum tolerate dose ( MTD ) determine sixth dose level reach , whichever occur first . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity first course therapy . After completion study treatment , patient follow annually . PROJECTED ACCRUAL : A total 36 patient accrue study .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis myelodysplastic syndrome ( MDS ) meet one follow criterion : FrenchAmericanBritish histological classification criterion Refractory anemia excess blast ( RAEB ) , define 519 % myeloblast bone marrow Patients 20 % blast consider acute myeloid leukemia ( per WHO classification system ) therefore exclude study Chronic myelomonocytic leukemia ( CMML ) , defined 1019 % myeloblasts bone marrow and/or 519 % blast blood WHO histological classification criterion RAEB1 , define 59 % myeloblast bone marrow RAEB2 , define 1019 % myeloblasts bone marrow and/or 519 % blast blood CMML2 , define 1019 % myeloblasts bone marrow and/or 519 % blast blood International Prognostic Scoring System ( IPSS ) score intermediate 2 ( 1.52.0 point base karyotype , cytopenia , bone marrow blast percentage ) high ( ≥ 2.5 point ) , set ≥ 5 % myeloblast Considered ineligible bone marrow transplantation firstline therapy PATIENT CHARACTERISTICS : Life expectancy ≥ 3 month ECOG performance status 02 Not pregnant nursing Negative pregnancy test Fertile patient must use effective doublemethod contraception 4 week , , 4 week completion study treatment No serious medical condition , laboratory abnormality , psychiatric illness , opinion treat physician , would preclude study participation preclude give informed consent No preexisting neurotoxicity neuropathy ≥ grade 2 No rash prior hypersensitivity allergic reaction ≥ grade 3 thalidomide Creatinine ≤ 2.0 mg/dL AST ALT ≤ 2.0 time upper limit normal Bilirubin ≤ 2 mg/dL Platelet count ≥ 50,000/mm^3 Absolute neutrophil count ≥ 500/mm^3 No malignancy within past 3 year except curatively treat carcinoma situ cervix nonmelanoma skin cancer No history thromboembolic event condition require use anticoagulation warfarin low molecularweight heparin No known suspect hypersensitivity azacitidine mannitol PRIOR CONCURRENT THERAPY : More 28 day since prior concurrent investigational agent MDS More 28 day since prior approve therapy MDS More 14 day since prior growth factor More 28 day since prior concurrent supraphysiologic dos ( equivalent &gt; 10 mg/day prednisone ) corticosteroids More 12 month since prior radiotherapy , chemotherapy , cytotoxic therapy treatment condition MDS No prior lenalidomide azacitidine No prior stem cell bone marrow transplantation No concurrent androgen , epoetin alfa , chemotherapy MDS</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
</DOC>